| treatment |
|
comparator |
All cause death | hospitalisation for heart failure | Death from any cause or hospitalization for heart failure | 30-day death | amelioration of Dyspnea at 24 h | Amelioration of Dyspnea at 6 h |
|
|
| Tolvaptan | acute heart failure, in all type of patients | vs placebo | NS | NS | - | - | - | - | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| All cause death | 0.55 [0.19 1.53] | p=1.00 | 0 | 240 | 1 | Udelson, | | hospitalisation for heart failure | 0.62 [0.33 1.14] | p=1.00 | 0 | 240 | 1 | Udelson, | | Death from any cause or hospitalization for heart failure | no data | | 30-day death | no data | | amelioration of Dyspnea at 24 h | no data | | Amelioration of Dyspnea at 6 h | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| EVEREST Clinical Status , 2007 | | | patients hospitalized with heart failure | | EVEREST Outcome, 2007 | | | patients hospitalized with heart failure | | Udelson, 2007 | tolvaptan 30 mg/day | placebo | patients with HF and reduced systolic function |
|
| Tolvaptan | heart failure, in advanced heart failure | vs placebo | - | - | - | - | - | - | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| All cause death | no data | | hospitalisation for heart failure | no data | | Death from any cause or hospitalization for heart failure | no data | | 30-day death | no data | | amelioration of Dyspnea at 24 h | no data | | Amelioration of Dyspnea at 6 h | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| EVEREST Clinical Status , 2007 | | | patients hospitalized with heart failure | | EVEREST Outcome, 2007 | | | patients hospitalized with heart failure |
|
| Tolvaptan | heart failure, in all type of patients | vs placebo | NS | NS | - | - | - | - | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| All cause death | 0.55 [0.19 1.53] | p=1.00 | 0 | 240 | 1 | Udelson, | | hospitalisation for heart failure | 0.62 [0.33 1.14] | p=1.00 | 0 | 240 | 1 | Udelson, | | Death from any cause or hospitalization for heart failure | no data | | 30-day death | no data | | amelioration of Dyspnea at 24 h | no data | | Amelioration of Dyspnea at 6 h | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| EVEREST Clinical Status , 2007 | | | patients hospitalized with heart failure | | EVEREST Outcome, 2007 | | | patients hospitalized with heart failure | | Udelson, 2007 | tolvaptan 30 mg/day | placebo | patients with HF and reduced systolic function |
|
